Dafna Frydman

Dafna Frydman

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MIMajdolen Istaiti
Majdolen Istaiti
DFDafna Frydman
Dafna Frydman
TDTama Dinur
Tama Dinur
Jeff SzerJeff Szer
Jeff Szer
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
Ari ZimranAri Zimran
Ari Zimran
Ambroxol hydrochloride (ABX), an oral mucolytic drug available over the counter for many years, acts as a pharmacological chaperone for mutant glucocerebrosidase, albeit at higher doses. Proof-of-concept reports have been published over the past decade on all three types of Gaucher disease (GD). Here, we assess the safety and efficacy of 12 months of 600 mg ambroxol per day in three groups of Type 1 GD patients with a suboptimal response to enzyme replacement therapy (ERT) or substrate reduction therapy (SRT), defined as platelet count < 100 × 103/L, lumbar spine bone density T-score < −2.0, and/or LysoGb1 > 200 ng/mL, and for a group of naïve patients who had abnormal values in two of these three parameters. We enrolled 40 patients: 28 ERT- or SRT-treated, and 12 naïve. There were no severe adverse effects (AEs). There were 24 dropouts, mostly due to AEs (n = 12), all transient, and COVID-19 (n = 7). Among the 16 completers, 5 (31.2%) had a >20% increase in platelet count, 6 (37.5%) had a >0.2 increase in T-score, and 3 (18.7%) had a >20% decrease in Lyso-Gb1. This study expands the number of patients exposed to high-dose ABX, showing good safety and satisfactory efficacy, and provides an additional rationale for adding off-label ABX to the arsenal of therapies that could be offered to patients with GD1 and a suboptimal response or those unable to receive ERT or SRT.

Verified
Journal Article
Open access
PDF file
DADavid Azoulay
David Azoulay
MNMira Naamad
Mira Naamad
DFDafna Frydman
Dafna Frydman
EBEllen Broide
Ellen Broide
Ari ZimranAri Zimran
Ari Zimran
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
Bleeding tendency, a prominent feature of patients with Gaucher disease (GD), is associated with abnormal platelet function. Brain-derived neurotrophic factor (BDNF) is a protein with neuroprotective potential stored in alpha granules of circulating platelets. Here we studied BDNF levels in 50 patients with type I GD (GD1) and their correlation with platelet activity and bleeding tendency. Flow cytometry was used to test unstimulated and stimulated measurement of platelet surface-activated expression of αIIbβ3 integrin, P-selectin and lysosomal-associated membrane protein (LAMP3/CD63). Serum and plasma BDNF levels were quantified using ELISA. The bleeding history was recorded by a bleeding questionnaire. Serum BDNF levels were positively correlated with platelet count and moderately correlated with unstimulated and stimulated platelet P-selectin expression. Patients with more than one bleeding manifestation were shown to have lower serum BDNF levels, albeit similar platelet count. Plasma BDNF levels were significantly elevated in splenectomized patients and showed a moderate positive correlation with stimulated platelet CD63 expression. These observations demonstrate the first association between BDNF levels in the peripheral blood with platelet dysfunction and increased bleeding manifestation. The role of measuring serum BDNF for assessing platelet alpha degranulation defects and bleeding risk in patients with GD and the general population needs further study.

Verified
Journal Article
Open access
PDF file
TDTama Dinur
Tama Dinur
PBPeter Bauer
Peter Bauer
SSSabine Schroeder
Sabine Schroeder
GKGuido Kramp
Guido Kramp
CBChristian Beetz
Christian Beetz
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
Glucosylsphingosine (lyso-Gb1) serves as a biomarker for evaluating disease activity in Gaucher disease (GD). While treatment-related changes are documented, the dynamics of lyso-Gb1 during untreated states remain poorly understood. This retrospective, longitudinal cohort study utilized a large GD database comprising 701 patients and over 6200 visits with lyso-Gb1 measurements. Patients with at least two untreated visits were included in the analysis (n = 272). A significant change was defined as ≥50 ng/mL for lyso-Gb1, ≥1 g/dL for hemoglobin, and ≥50 × 109/L for platelet count. Multivariable logistic regression analyses identified clinical factors associated with lyso-Gb1 decline or an increase. During untreated states, 35 patients (12.9%; 95% CI 9.4–17.5%) exhibited a decline in lyso-Gb1, with a median decrease of 96.3 ng/mL. This decline was more common in females (OR 3.50, p = 0.032) and associated with higher initial lyso-Gb1 levels (p < 0.001) and baseline hemoglobin (p = 0.032). An increase in lyso-Gb1 was observed in 98 patients (36.0%; 95% CI 30.5–41.9%), with a median rise of 135.1 ng/mL. This increase correlated with lower baseline platelet counts (p = 0.003), lower baseline hemoglobin (p = 0.002), and longer follow-up duration (p = 0.001). In many cases, lyso-Gb1 increases were observed without a preceding change in hemoglobin or platelet count. In summary, declines in lyso-Gb1 in untreated states are rare but possible. The association with female sex may reflect inflammatory effects. Although increases in lyso-Gb1 were expected without treatment, they occurred mainly in patients with higher disease severity markers. Nevertheless, most patients in the untreated states remained stable within ±50 ng/mL. These findings demonstrate a heterogeneous trajectory of lyso-Gb1 across untreated states and highlight the importance of interpreting lyso-Gb1 changes within the clinical context when making treatment decisions.

26 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ari ZimranAri Zimran
Ari Zimran
JBJaco Botha
Jaco Botha
RERichard Eastell
Richard Eastell
Can FiciciogluCan Ficicioglu
Can Ficicioglu
RFRichard D. Finkelman
Richard D. Finkelman
DHDerralynn Hughes
Derralynn Hughes
Background: Despite the availability of effective therapies for Gaucher disease (GD), management of skeletal disease manifestations remains challenging. Methods: This phase 4 SHP-GCB-402 study evaluated the effect of velaglucerase alfa on lumbar spine (LS) bone outcomes in patients with type 1 GD. Results: Twenty-one patients with documented bone pathology received ≥1 dose of velaglucerase alfa 60 U/kg; 16 completed this study. The primary endpoint—change from baseline to 24 months in an LS bone mineral density (BMD) Z-score measured by dual-energy X-ray absorptiometry—showed a numerical improvement from baseline (mean [SD] −1.93 [0.88]) to 24 months (−1.76 [1.00]), although statistical significance was not reached (p = 0.1077). These changes are not consistent with previous velaglucerase alfa studies. To contextualize these findings, a pooled analysis of 24-month data from previous velaglucerase alfa trials was conducted. In this cohort (n = 40), a statistically significant mean (SD) increase in the LS BMD Z-score of 0.55 (0.58; p < 0.0001) was observed, supporting the therapeutic potential of velaglucerase alfa in improving skeletal outcomes. Additionally, SHP-GCB-402 demonstrated a significant reduction in the bone marrow burden (BMB) score (mean change from baseline: −3.0 [2.27]; p = 0.0005), indicating a positive effect on bone marrow infiltration. All patients experienced ≥1 treatment-emergent adverse event, mostly of mild/moderate severity. Conclusions: The observed numerical improvements in BMD and significant improvements in BMB in SHP-GCB-402 along with pooled BMD data suggest that velaglucerase alfa may confer skeletal benefits while maintaining a consistent safety profile.

22 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MBMichal Becker-Cohen
Michal Becker-Cohen
AZAri Zimran
Ari Zimran
DADavid Arkadir
David Arkadir
OMOrly Manor
Orly Manor
OPOra Paltiel
Ora Paltiel
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
Carriers of GBA1 gene variants (GBA1-carriers) are at increased risk of developing Parkinson disease (PD). Identifying prodromal PD before the onset of motor symptoms may enable interventions aimed at delaying or preventing disease progression. For the past nine years, the Gaucher Unit at Shaare Zedek Medical Center has screened GBA1-carriers for early prodromal PD features using a battery of non-invasive clinical, cognitive, motor, olfactory, and neuroimaging assessments. This study presents longitudinal follow-up data from individuals who showed increased echogenicity on transcranial sonography (TCS) and/or olfactory decline at their initial prodromal evaluation.Twenty-six mono- and bi-allelic GBA1-carriers, including patients with Gaucher disease, underwent reassessment after a median (range) follow-up of 5 (1–8) years. The same battery of non-invasive assessments was administered and compared with baseline findings.At the group level, significant changes were observed only in bowel movement frequency (p = 0.011) and color discrimination performance (p = 0.028). However, individual-level analyses revealed substantial heterogeneity. Eight participants demonstrated evidence of progression, predominantly in imaging, sensory/autonomic, cognitive, and sleep-related domains. Ten individuals exhibited at least three abnormal prodromal features at reassessment and were considered at increased risk for PD. Seven of these underwent ^18F-FDOPA PET-CT imaging, which confirmed abnormal dopaminergic function. Two participants subsequently received a clinical diagnosis of PD. Despite limited cohort-level changes over time, longitudinal individualized monitoring identified progressive abnormalities in a subset of GBA1-carriers. These findings support personalized follow-up strategies to detect prodromal PD and may help identify candidates for emerging disease-modifying therapies in this high-risk population.

Verified
Journal Article
Open access
PDF file
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
Ari ZimranAri Zimran
Ari Zimran
TDTama Dinur
Tama Dinur
DFDafna Frydman
Dafna Frydman
ESElena Shulman
Elena Shulman
MSMichal Saltsman
Michal Saltsman
Bleeding in Gaucher disease (GD) is not fully explained by thrombocytopenia and coagulation disorders. Previous studies have shown impaired agonist-induced cluster of differentiation (CD) 62P (CD62P/P-selectin) responses, but their persistence over time is unknown. This retrospective longitudinal observational study characterized platelet activation and secretion responses over time and factors associated with persistent abnormalities. Whole-blood flow cytometry studies from 333 patients with GD with at least two assessments were analyzed. Platelet activation complex-1 (PAC1), CD62P, and CD63 responses were categorized longitudinally. Patients contributed 949 visits over a median follow-up of 2.3 years. Persistent CD62P abnormality was most frequent (92/333, 27.6%), compared with PAC1 (45/329, 13.7%) and CD63 (9/328, 2.7%). PAC1 abnormalities were more often dynamic, whereas CD62P abnormalities were frequent and persistent, most often involving thrombin receptor-activating peptide 6 (TRAP-6) and cross-linked collagen-related peptide (CRP-XL). Lower platelet count was independently associated with persistent CD62P abnormality, although approximately half of affected patients had platelet counts ≥150 × 109/L. Treatment throughout follow-up was associated with lower odds of persistent CD62P and CD63 abnormalities. Impaired CD62P expression was the predominant persistent abnormality, consistent with preferential impairment of α-granule secretion. Platelet function changed over time, supporting reassessment in patients with bleeding manifestations and before procedures when previous testing is remote or clinical status has changed.